U.S. Food and Drug Administration Approves Opdivo® (nivolumab) With Chemotherapy As Neoadjuvant Treatment for Certain Adult Patients With Resectable Non-small Cell Lung Cancer.
https://www.cmlviz.com/stocks/BMY/news/b/2022/03/04/fda-approves-expanded-use-of-bristol-myers-cancer-drug-opdivo
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.